Autologous T cells are genetically engineered to express a dual-target chimeric antigen receptor recognizing CD44 and CD133 on glioblastoma and cancer stem-like cells. CAR engagement activates T-cell cytotoxicity via CD3-zeta/co-stimulatory signaling, while an incorporated truncated IL-7Rα intracellular module enhances T-cell survival, persistence, and functional activity. Cells are delivered locoregionally via an Ommaya reservoir to maximize tumor exposure and reduce antigen escape through dual targeting.